DALBAVANCIN HYDROCHLORIDE

Post-LOE

dalbavancin hydrochloride

Fresenius Kabi

ANDAINTRAVENOUSPOWDER

Approved

Feb 2026

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DALBAVANCIN HYDROCHLORIDE (dalbavancin hydrochloride) by Fresenius Kabi is [see microbiology ()] . Approved for skin structure infections (absssi) caused by designated susceptible strains of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-susceptible, methicillin-resistant isolates), streptococcus pyogenes and 3 more indications. First approved in 2026.

Drug data last refreshed 23h ago

Mechanism of Action

[see Microbiology ()] .

Indications (6)

skin structure infections (ABSSSI) caused by designated susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible methicillin-resistant isolates)

Worked on DALBAVANCIN HYDROCHLORIDE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.